Hepatitis C Articles

  FDA-approved Drugs

  Experimental Drugs

FDA-approved Drugs

Prolonged Therapy with Pegylated Interferon/Ribavirin May Improve Odds of Sustained HCV Clearance

Treatment Duration and Response in Patients with Genotype 2 or 3 HCV Infection

Response to PegIntron/ribavirin Leads to Stabilization of Fibrosis in Liver Transplant Recipients

Does SVR after Treatment with Pegasys/ribavirin Constitute a Cure for Chronic Hepatitis C?

Past Psychiatric Disorders Do Not Reduce Hepatitis C Treatment Effectiveness in Genotype 2/3 Patients

Selected Patients with Genotype 1 HCV May Attain SVR by Extending Treatment Duration to 72 Weeks

400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV

Cannabis Use Predicts Severe Liver Steatosis in Patients with Chronic Hepatitis C

Rapid Virological Response Predicts Sustained Response and Can Help Optimize HCV Treatment

HCV-796 Shows Antiviral Activity in Combination with Pegylated Interferon

Albumin Interferon May Be as Effective as Pegylated Interferon with Less Frequent Dosing

Two Studies Yield Mixed Results for HCV Polymerase Inhibitor Valopicitabine

Pegylated Interferon plus Ribavirin in Patients with HBV-HCV Dual Infection

14 Weeks of Treatment with PegIntron plus Ribavirin Is Non-inferior to 24 Weeks in Rapid Responders with HCV Genotype 2 or 3

Adding Celgosivir to Standard Hepatitis C Therapy Increases the Likelihood of Early Response Rate in Prior Non-responders

Combining Experimental HCV Inhibitors Boceprevir and NM 107 Enhances Anti-HCV Activity and Suppresses Emergence of Resistance

In Vitro Studies Suggest Promising Outcomes with New HCV Protease Inhibitor ACH 806 in Combination with Interferon, Telaprevir, or NM 107

HOME